Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis.
文献摘要
Objective Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events (MACE) and improves angina, this study aims to evaluate its differential efficacy across varying hemoglobin (Hb) levels. Methods This was a subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled phase W trial. Patients with coronary artery disease (CAD) were stratified into two groups based on baseline Hb levels: Group A (Hb 140 g/L, n=1,208). The primary endpoint was MACE; secondary endpoints included non-fatal myocardial infarction (MI), non-fatal stroke, and all-cause mortality. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards models. Results In Group A, MUSKARDIA significantly reduced MACE risk (HR=0.45, 95% CI: 0.21-0.96, P=0.038), with a 68% reduction in non-fatal MI risk (P=0.036). Non-fatal stroke and all-cause mortality showed no significant differences. Adverse events were lower in the MUSKARDIA group (15.9% vs. 17.6%). In Group B, no significant MACE benefit was observed (P=0.354), with a trend toward increased non-fatal MI risk (HR=1.88). Non-fatal stroke and all-cause mortality were similar between groups. Adverse events were slightly higher (21.2% vs. 18.3%). Conclusions MUSKARDIA demonstrated significant cardiovascular protective effects in CAD patients with Hb 140 g/L. This highlights its cardiovascular protective role in high-risk populations characterized by greater ischemic risk and inadequate myocardial oxygen supply.